Merck
  • Home
  • Search Results
  • Iodinated contrast does not alter clotting dynamics in acute ischemic stroke as measured by thromboelastography.

Iodinated contrast does not alter clotting dynamics in acute ischemic stroke as measured by thromboelastography.

Stroke (2013-12-29)
Mark M McDonald, Joancy M Archeval-Lao, Chunyan Cai, Hui Peng, Navdeep Sangha, Stephanie A Parker, Jeremy Wetzel, Stephen A Riney, Matt F Cherches, Greer J Guthrie, Tiffany C Roper, Jorge F Kawano-Castillo, Renga Pandurengan, Mohammad H Rahbar, James C Grotta
ABSTRACT

Iodinated contrast agents used for computed tomography angiography (CTA) may alter fibrin fiber characteristics and decrease fibrinolysis by tissue plasminogen activator (tPA). Thromboelastography (TEG) measures the dynamics of coagulation and correlates with thrombolysis in acute ischemic stroke patients. We hypothesized that receiving CTA before tPA will not impair thrombolysis as measured by TEG. Acute ischemic stroke patients receiving 0.9 mg/kg tPA <4.5 hours of symptom onset were prospectively enrolled. For CTA, 350 mg/dL of iohexol or 320 mg/dL of iodixanol at a dose of 2.2 mL/kg was administered. TEG was measured before tPA and 10 minutes after tPA bolus. CTA timing was left to the discretion of the treating physician. Of 136 acute ischemic stroke patients who received tPA, 47 had CTA before tPA bolus, and 42 had either CTA after tPA and post-tPA TEG draw or no CTA (noncontrast group). Median change in clot lysis (LY30) after tPA was 95.3% in the contrast group versus 95.0% in the noncontrast group (P=0.74). Thus, tPA-induced thrombolysis did not differ between contrast and noncontrast groups. Additionally, there was no effect of contrast on any pre-tPA TEG value. Our data do not support an effect of iodinated contrast agents on clot formation or tPA activity.

MATERIALS
Product Number
Brand
Product Description

碘克沙醇, European Pharmacopoeia (EP) Reference Standard